Glycosaminoglycan-binding cytokines as tumor markers

Proteomics

Volumn 8, Issue 16, 2008, Pages 3350-3359

  Muramatsu, Takashi ^a   Muramatsu, Hisako ^b  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokines; FGF; HGF; Midkine; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; GLYCOSAMINOGLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; INTERLEUKIN 8; MIDKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLEIOTROPHIN; SCATTER FACTOR; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN C;

ANGIOGENESIS; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER INVASION; HUMAN; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; TUMOR; TUMOR GROWTH;

CYTOKINES; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCANS; HUMANS; INTERLEUKIN-8; NEOPLASMS; PROTEIN BINDING; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 50449111339     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800042     Document Type: Review

References (146)

1. Muramatsu, T., Muramatsu, H., Kojima, T., Identification of proteoglycan-binding proteins. Methods Enzymol. 2006, 416, 263-278.
2. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., Blundell, T. L., Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407, 1029-1034.
3. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11-22.
4. Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G. et al., Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 1999, 5, 1369-1379.
5. Gokhale, A. S., Haddad, R. I., Cavacini, L. A., Wirth, L. et al., Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral. Oncol. 2005, 41, 70-76.
6. Allen, C., Duffy, S., Teknos, T., Islam, M. et al., Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin. Cancer Res. 2007, 13, 3182-3190.
7. Linkov, F., Lisovich, A., Yurkovetsky, Z., Marrangoni, A. et al., Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 102-107.
8. Ueda, T., Shimada, E., Urakawa, T., Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J. Gastroenterol. 1994, 29, 423-429.
9. Retzlaff, S., Padro, T., Koch, P., Oelmann, E. et al., Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma. Oncol. Rep. 2002, 9, 525-527.
10. Wierda, W. G., Johnson, M. M., Do, K. A., Manshouri, T. et al., Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br. J. Haematol. 2003, 120, 452-456.
11. Mayerhofer, K., Bodner, K., Bodner-Adler, B., Schindl, M. et al., Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer 2001, 91, 388-393.
12. Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F. et al., Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 981-987.
13. Lokshin, A. E., Winans, M., Landsittel, D., Marrangoni, A. M. et al., Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol. 2006, 102, 244-251.
14. Masood, R., Cai, J., Tulpule, A., Zheng, T. et al., Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. Clin. Cancer Res. 2001, 7, 2693-2702.
15. Tas, F., Duranyildiz, D., Oguz, H., Camlica, H. et al., Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006, 24, 492-496.
16. Kaminska, J., Kowalska, M., Kotowicz, B., Fuksiewicz, M. et al., Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006, 70, 115-125.
17. Kozlowski, L., Zakrzewska, I., Tokajuk, P., Wojtukiewicz, M. Z., Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 2003, 48, 82-84.
18. Macri, A., Versaci, A., Loddo, S., Scuderi, G. et al., Serum levels of interleukin 1β, interleukin 8 and tumour necrosis factor α as markers of gastric cancer. Biomarkers 2006, 11, 184-193.
19. Ruka, W., Rutkowski, P., Kaminska, J., Rysinska, A., Steffen, J., Alterations of routine blood tests in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance. Ann. Oncol. 2001, 12, 1423-1432.
20. Hefler, L., Tempfer, C., Heinze, G., Mayerhofer, K. et al., Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br. J. Cancer 1999, 81, 855-859.
21. Monti, P., Leone, B. E., Marchesi, F., Balzano, G. et al., The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of anti-malignant activity. Cancer Res. 2003, 63, 7451-7461.
22. Lebrecht, A., Grimm, C., Lantzsch, T., Ludwig, E. et al., Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004, 25, 14-17.
23. Dehqanzada, Z. A., Storrer, C. E., Hueman, M. T., Foley, R. J. et al., Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin. Cancer Res. 2006, 12, 478-486.
24. Salven, P.,Manpaa, H.,Orpana, A.,Alitalo, K., Joensuu, H., Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 1997, 3, 647-651.
25. Kraft, A., Weindel, K., Ochs, A., Marth, C. et al., Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85, 178-187.
26. Tang, Z. Y., Ye, S. L., Liu, Y. K., Qin, L. X. et al., A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130, 187-196.
27. Guo, R. P., Zhong, C., Shi, M., Zhang, C. Q. et al., Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006, 132, 547-555.
28. Iguchi, H., Yokota, M., Fukutomi, M., Uchimura, K. et al., A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2002, 21, 309-313.
29. Poon, R. T., Lau, C. P., Cheung, S. T., Yu, W. C., Fan, S. T., Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003, 63, 3121-3126.
30. Imoto, H., Osaki, T., Taga, S., Ohgami, A. et al., Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 1998, 115, 1007-1014.
31. Laack, E., Kohler, A., Kugler, C., Dierlamm, T. et al., Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann. Oncol. 2002, 13, 1550-1557.
32. Tamura, M., Oda, M., Matsumoto, I., Tsunezuka, Y. et al., The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann. Surg. Oncol. 2004, 11, 928-933.
33. Kaya, A., Ciledag, A., Gulbay, B. E., Poyraz, B. M. et al., The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir. Med. 2004, 98, 632-636.
34. Dudek, A. Z., Mahaseth, H., Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest. 2005, 23, 193-200.
35. Shimanuki, Y., Takahashi, K., Cui, R., Hori, S. et al., Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005, 183, 29-42.
36. Salven, P., Ruotsalainen, T., Mattson, K., Joensuu, H., High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 1998, 79, 144-146.
37. Hyodo, I., Doi, T., Endo, H., Hosokawa, Y. et al., Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur. J. Cancer 1998, 34, 2041-2045.
38. Kumar, H., Heer, K., Lee, P. W., Duthie, G. S. et al., Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res. 1998, 4, 1279-1285.
39. Fujisaki, K., Mitsuyama, K., Toyonaga, A., Matsuo, K., Tanikawa, K., Circulating vascular endothelial growth factor in patients with colorectal cancer. Am. J. Gastroenterol. 1998, 93, 249-252.
40. Chin, K. F., Greenman, J., Gardiner, E., Kumar, H. et al., Preoperative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br. J. Cancer 2000, 83, 1425-1431.
41. Takeda, A., Shimada, H., Imaseki, H., Okazumi, S. et al., Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathological factors and tumor markers. Oncol. Rep. 2000, 7, 333-338.
42. Broll, R., Erdmann, H., Duchrow, M., Oevermann, E. et al., Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur. J. Surg. Oncol. 2001, 27, 37-42.
43. Berglund, A., Molin, D., Larsson, A., Einarsson, R., Glimelius, B., Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann. Oncol. 2002, 13, 1430-1437.
44. Werther, K., Sorensen, S., Christensen, I. J., Nielsen, H. J., Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. Acta Oncol. 2003, 42, 837-845.
45. Kitamura, M., Toi, M., Arai, K., Iwasaki, Y. et al., Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol. Rep. 1998, 5, 1419-1424.
46. Shimada, H., Takeda, A., Nabeya, Y., Okazumi, S. I. et al., Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001, 92, 663-669.
47. Yamamoto, S., Konishi, I., Mandai, M., Kuroda, H. et al., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 1997, 76, 1221-1227.
48. Obermair, A., Tempfer, C., Hefler, L., Preyer, O. et al., Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br. J. Cancer 1998, 77, 1870-1874.
49. Cooper, B. C., Ritchie, J. M., Broghammer, C. L., Coffin, J. et al., Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin. Cancer Res. 2002, 8, 3193-3197.
50. Alvarez Secord, A., Sayer, R., Snyder, S. A., Broadwater, G. et al., The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol. Oncol. 2004, 94, 74-79.
51. Hefler, L. A., Zeillinger, R., Grimm, C., Sood, A. K. et al., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. 2006, 103, 512-517.
52. Granato, A. M., Nanni, O., Falcini, F., Folli, S. et al., Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: Useful as diagnostic tools? Breast Cancer Res. 2004, 6, R38-R45.
53. Coskun, U., Gunel, N., Toruner, F. B., Sancak, B. et al., Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 2003, 50, 41-46.
54. Voorzanger-Rousselot, N., Juillet, F., Mareau, E., Zimmermann, J. et al., Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: A crossectional and longitudinal evaluation. Br. J. Cancer 2006, 95, 506-514.
55. Qian, C. N., Zhang, C. Q., Guo, X., Hong, M. H. et al., Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000, 88, 255-261.
56. Teknos, T. N., Cox, C., Yoo, S., Chepeha, D. B. et al., Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002, 24, 1004-1011.
57. Druzgal, C. H., Chen, Z., Yeh, N. T., Thomas, G. R. et al., A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck 2005, 27, 771-784.
58. Shang, Z. J., Li, J. R., Li, Z. B., Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int. J. Oral. Maxillofac. Surg. 2002, 31, 495-498.
59. Dosquet, C., Coudert, M. C., Lepage, E., Cabane, J., Richard, F., Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res. 1997, 3, 2451-2458.
60. Sato, K., Tsuchiya, N., Sasaki, R., Shimoda, N. et al., Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn. J. Cancer Res. 1999, 90, 874-879.
61. Lebrecht, A., Ludwig, E., Huber, A., Klein, M. et al., Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol. Oncol. 2002, 85, 32-35.
62. Mitsuhashi, A., Suzuka, K., Yamazawa, K., Matsui, H. et al., Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005, 103, 724-730.
63. Sasaki, H., Yukiue, H., Kobayashi, Y., Nakashima, Y. et al., Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg. Today 2001, 31, 1038-1040.
64. Osella-Abate, S., Quaglino, P., Savoia, P., Leporati, C. et al., VEGF-165 serum levels and tyrosinase expression in melanoma patients: Correlation with the clinical course. Melanoma Res. 2002, 12, 325-334.
65. Graeven, U., Andre, N., Achilles, E., Zornig, C., Schmiegel, W., Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol. 1999, 125, 577-581.
66. Hayes, A. J., Mostyn-Jones, A., Koban, M. U., A'Hern, R. et al., Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br. J. Surg. 2004, 91, 242-247.
67. Aguayo, A., Kantarjian, H. M., Estey, E. H., Giles, F. J. et al., Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95, 1923-1930.
68. Ben Arush, M. W., Ben Barak, A., Maurice, S., Livne, E., Serum VEGF as a significant marker of treatment response in hodgkin lymphoma. Pediatr. Hematol. Oncol. 2007, 24, 111-115.
69. Niki, T., Iba, S., Tokunou, M., Yamada, T. et al., Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 2000, 6, 2431-2439.
70. Ohta, Y., Nozawa, H., Tanaka, Y., Oda, M., Watanabe, Y., Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2000, 119, 804-813.
71. Tamura, M., Oda, M., Tsunezuka, Y., Matsumoto, I. et al., Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 2004, 126, 342-346.
72. Mathur, S. P., Mathur, R. S., Gray, E. A., Lane, D. et al., Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol. Oncol. 2005, 98, 467-483.
73. Vihinen, P. P., Hilli, J., Vuoristo, M. S., Syrjanen, K. J. et al., Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol. 2007, 46, 678-684.
74. Wang, T. B., Deng, M. H., Qiu, W. S., Dong, W. G., Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J. Gastroenterol. 2007, 13, 1794-1797.
75. Ren, Y., Cao, B., Law, S., Xie, Y. et al., Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: A prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 2005, 11, 6190-6197.
76. Hjorth-Hansen, H., Seidel, C., Lamvik, J., Borset, M. et al., Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur. J. Haematol. 1999, 62, 129-134.
77. Gohji, K., Nomi, M., Niitani, Y., Kitazawa, S. et al., Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J. Clin. Oncol. 2000, 18, 2963-2971.
78. Fukuura, T., Miki, C., Inoue, T., Matsumoto, K., Suzuki, H., Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br. J. Cancer 1998, 78, 454-459.
79. Miki, C., Inoue, Y., Hiro, J., Ojima, E. et al., Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes A and B colorectal cancer: Results of a five-year study. Dis. Colon Rectum. 2006, 49, 1710-1718.
80. Taniguchi, T., Toi, M., Inada, K., Imazawa, T. et al., Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res. 1995, 1, 1031-1034.
81. Toi, M., Taniguchi, T., Ueno, T., Asano, M. et al., Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin. Cancer Res. 1998, 4, 659-664.
82. Sheen-Chen, S. M., Liu, Y. W., Eng, H. L., Chou, F. F., Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 715-717.
83. Pruefer, F. G., Unger-Saldana, K., Mohamier, L., Ramirez, M. et al., Tumor HGF lacks prognostic significance in Mexican breast cancer patients. J. Exp. Clin. Cancer Res. 2006, 25, 357-364.
84. Hioki, O., Watanabe, A., Minemura, M., Tsuchida, T., Clinical significance of serum hepatocyte growth factor levels in liver diseases. J. Med. 1993, 24, 35-46.
85. Hillan, K. J., Logan, M. C., Ferrier, R. K., Bird, G. L. et al., Hepatocyte proliferation and serum hepatocyte growth factor levels in patients with alcoholic hepatitis. J. Hepatol. 1996, 24, 385-390.
86. Mendenhall, C. L., Roos, F., Moritz, T. E., Roselle, G. A. et al., Human hepatocyte growth factor in alcoholic liver disease: A comparison with change in alpha-fetoprotein. Department of Veterans Affairs Cooperative Study Group 275. Alcohol. Clin. Exp. Res. 1996, 20, 1625-1630.
87. Yamagami, H., Moriyama, M., Matsumura, H., Aoki, H. et al., Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 2002, 95, 824-834.
88. Hsia, C. Y., Huo, T. I., Chiang, S. Y., Lu, M. F. et al., Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 2007, 33, 208-212.
89. Taniguchi, T., Kitamura, M., Arai, K., Iwasaki, Y. et al., Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br. J. Cancer 1997, 75, 673-677.
90. Tanaka, K., Miki, C., Wakuda, R., Kobayashi, M. et al., Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand. J. Gastroenterol. 2004, 39, 754-760.
91. Naughton, M., Picus, J., Zhu, X., Catalona, W. J. et al., Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J. Urol. 2001, 165, 1325-1328.
92. Hsiao, L. T., Lin, J. T., Yu, I. T., Chiou, T. J. et al., High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur. J. Haematol. 2003, 70, 282-289.
93. Alexandrakis, M. G., Passam, F. H., Sfiridaki, A., Kandidaki, E. et al., Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity. Am. J. Hematol. 2003, 72, 229-233.
94. Vesely, D., Astl, J., Lastuvka, P., Matucha, P. et al., Serum levels of IGF-I, HGF, TGFβ1, bFGF and VEGF in thyroid gland tumors. Physiol. Res. 2004, 53, 83-89.
95. Takigawa, N., Segawa, Y., Maeda, Y., Takata, I., Fujimoto, N., Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. Lung Cancer 1997, 17, 211-218.
96. Bharti, A., Ma, P. C., Maulik, G., Singh, R. et al., Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004, 24, 1031-1038.
97. Fujimoto, K., Ichimori, Y., Kakizoe, T., Okajima, E. et al., Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem. Biophys. Res. Commun. 1991, 180, 386-392.
98. Fujimoto, K., Ichimori, Y., Yamaguchi, H., Arai, K. et al., Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn. J. Cancer Res. 1995, 86, 182-186.
99. Rasmuson, T., Grankvist, K., Jacobsen, J., Ljungberg, B., Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur. J. Cancer 2001, 37, 2199-2203.
100. Horstmann, M., Merseburger, A. S., von der Heyde, E., Serth, J. et al., Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J. Cancer Res. Clin. Oncol. 2005, 131, 715-722.
101. Salven, P., Teerenhovi, L., Joensuu, H., A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999, 94, 3334-3339.
102. Sliutz, G., Tempfer, C., Obermair, A., Dadak, C., Kainz, C., Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995, 15, 2675-2677.
103. Pichon, M. F., Moulin, G., Pallud, C., Pecking, A., Floiras, J. L., Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res. 2000, 20, 1189-1194.
104. Colomer, R., Aparicio, J., Montero, S., Guzman, C. et al., Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br. J. Cancer 1997, 76, 1215-1220.
105. Joensuu, H., Anttonen, A., Eriksson, M., Makitaro, R. et al., Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002, 62, 5210-5217.
106. Ueno, K., Inoue, Y., Kawaguchi, T., Hosoe, S., Kawahara, M., Increased serum levels of basic fibroblast growth factor in lung cancer patients: Relevance to response of therapy and prognosis. Lung Cancer 2001, 31, 213-219.
107. Ruotsalainen, T., Joensuu, H., Mattson, K., Salven, P., High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 1492-1495.
108. Brattstrom, D., Bergqvist, M., Hesselius, P., Larsson, A. et al., Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002, 37, 57-63.
109. Kyrtsonis, M. C., Vassilakopoulos, T. P., Siakantaris, M. P., Kokoris, S. I. et al., Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur. J. Haematol. 2004, 72, 252-258.
110. Hsu, P. I., Chow, N. H., Lai, K. H., Yang, H. B. et al., Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res. 1997, 17, 2803-2809.
111. Poon, R. T., Ng, I. O., Lau, C., Yu, W. C. et al., Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 2001, 182, 298-304.
112. Leunig, A., Tauber, S., Spaett, R., Grevers, G., Leunig, M., Basic fibroblast growth factor in serum and urine of patients with head and neck cancer. Oncol. Rep. 1998, 5, 955-958.
113. Dietz, A., Rudat, V., Conradt, C., Weidauer, H. et al., Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 2000, 22, 666-673.
114. Meyer, G. E., Yu, E., Siegal, J. A., Petteway, J. C. et al., Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995, 76, 2304-2311.
115. Aigner, A., Brachmann, P., Beyer, J., Jager, R. et al., Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann. Oncol. 2003, 14, 1525-1529.
116. Le Page, C., Ouellet, V., Madore, J., Hudson, T. J. et al., From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int. J. Cancer 2006, 118, 1750-1758.
117. Mroczko, B., Szmitkowski, M., Niklinski, J., Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer. Clin. Chem. Lab. Med. 2001, 39, 374-379.
118. Mroczko, B., Groblewska, M., Wereszczynska-Siemiatkowska, U., Kedra, B. et al., The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin. Chim. Acta 2006, 371, 143-147.
119. Groblewska, M., Mroczko, B., Wereszczynska-Siemiatkowska, U., Mysliwiec, P. et al., Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin. Chem. Lab. Med. 2007, 45, 30-34.
120. Kurtz, A., Schulte, A. M., Wellstein, A., Pleiotrophin and midkine in normal development and tumor biology. Crit. Rev. Oncol. 1995, 6, 151-177.
121. Muramatsu, T., Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. 2002, 132, 359-371.
122. Deuel, T. F., Zhang, N., Yeh, H. J., Silos-Santiago, I., Wang, Z. Y., Pleiotrophin: A cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys. 2002, 397, 162-171.
123. Kadomatsu, K., Muramatsu, T., Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004, 204, 127-143.
124. Choudhuri, R., Zhang, H. T., Donnini, S., Ziche, M., Bicknell, R., An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997, 57, 1814-1819.
125. Sumi, Y., Muramatsu, H., Takei, Y., Hata, K. et al., Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J. Cell Sci. 2002, 115, 2659-2667.
126. Muramatsu, H., Song, X. J., Koide, N., Hada, H. et al., Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J. Biochem. 1996, 119, 1171-1175.
127. Song, X.-J., Muramatsu, H., Aridome, K., Aikou, T. et al., The serum level of midkine, a heparin-bindin growth factor, as a tumor marker. Biomed. Res. 1997, 18, 375-381.
128. Ikematsu, S., Yano, A., Aridome, K., Kikuchi, M. et al., Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer 2000, 83, 701-706.
129. Ikematsu, S., Nakagawara, A., Nakamura, Y., Sakuma, S. et al., Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br. J. Cancer 2003, 88, 1522-1526.
130. Shimada, H., Nabeya, Y., Tagawa, M., Okazumi, S. et al., Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003, 94, 628-632.
131. Soulie, P., Heroult, M., Bernard-Pierrot, I., Caruelle, D. et al., Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients. Cancer Detect. Prev. 2004, 28, 319-324.
132. Mashour, G. A., Driever, P. H., Hartmann, M., Drissel, S. N. et al., Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin. Cancer Res. 2004, 10, 5677-5683.
133. Obata, Y., Kikuchi, S., Lin, Y., Yagyu, K. et al., Serum midkine concentrations and gastric cancer. Cancer Sci. 2005, 96, 54-56.
134. Salama, R. M. H., Muramatsu, H., Kobayashi, H., Nomura, S. et al., Serum levels of midkine, a heparin-binding growth factor, increase in both malignant and gynecological tumor. Reprod. Immunol. Biol. 2006, 21, 64-70.
135. Jia, H. L., Ye, Q. H., Qin, L. X., Budhu, A. et al., Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 2007, 13, 1133-1139.
136. Krzystek-Korpacka, M., Matusiewicz, M., Diakowska, D., Grabowski, K. et al., Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in oesophageal squamous cell carcinoma. Biomarkers 2007, 12, 403-413.
137. Maruyama, K., Muramatsu, H., Ishiguro, N., Muramatsu, T., Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2004, 50, 1420-1429.
138. Shimizu, E., Hashimoto, K., Salama, R. H., Watanabe, H. et al., Two clusters of serum midkine levels in drug-naive patients with schizophrenia. Neurosci. Lett. 2003, 344, 95-98.
139. Salama, R. H., Muramatsu, H., Shimizu, E., Hashimoto, K. et al., Increased midkine levels in sera from patients with Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 611-616.
140. Jager, R., List, B., Knabbe, C., Souttou, B. et al., Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br. J. Cancer 2002, 86, 858-863.
141. Klomp, H. J., Zernial, O., Flachmann, S., Wellstein, A., Juhl, H., Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients. Clin. Cancer Res. 2002, 8, 823-827.
142. Yeh, H. S., Chen, H., Manyak, S. J., Swift, R. A. et al., Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br. J. Haematol. 2006, 133, 526-529.
143. Soulie, P., Heroult, M., Bernard, I., Kerros, M. E. et al., Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. J. Immunoassay Immunochem. 2002, 23, 33-48.
144. Wynendaele, W., Derua, R., Hoylaerts, M. F., Pawinski, A. et al., Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Ann. Oncol. 1999, 10, 965-971.
145. Dittadi, R., Meo, S., Fabris, F., Gasparini, G. et al., Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int. J. Biol. Markers 2001, 16, 87-96.
146. Ranieri, G., Coviello, M., Chiriatti, A., Stea, B. et al., Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol. Rep. 2004, 11, 435-439.